Immune checkpoint inhibitors (ICIs) have shown significant promise in treating tumors. Immune checkpoint inhibitors are a form of immunotherapy, which redi | Immunology ...
The global cancer immunotherapy market was valued at more than US$ 92.11 billion in 2024. It is anticipated to increase at a CAGR of 12.84% between 2024 and 2031. The worldwide cancer immunotherapy ...
The market is taking notice. Analysts predict the global immunotherapy market will soar to $258 billion by 2031, powered by breakthroughs like checkpoint inhibitors and next-gen therapies.
Find out more about the emerging field of glycobiology, which could potentially lead to a new type of cancer immunotherapy.
TuHURA Biosciences, Inc. (Nasdaq: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies ...
A deep learning radiomic biomarker has been developed and validated to predict responses to immune checkpoint inhibitors in ...
New treatments and adverse events impacting patient quality of life were among the topics of interest in 2024.
CTLA-4 is an immune checkpoint receptor that suppresses T cell ... This mechanism has made CTLA-4 inhibitors an essential part of cancer immunotherapy, particularly in treating advanced-stage ...
New insights into the impact of checkpoint inhibitors on the immune system may enhance cancer treatment strategies. A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback